PLUS THERAPEUTICS, INC.

For the period ended Jun 30, 2025. Filed Aug 14, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2025 · Filed Aug 14, 2025

CNSY$0.68+19.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations

(in thousands, except share and per share data)

	For the Three Months Ended June 30,		For the Six Months Ended June 30,
	2025	2024	2025	2024
Grant revenue	$1,390	$1,279	$2,449	$2,956
Operating expenses:
Research and development	1,246	2,773	3,002	5,536
General and administrative	1,682	2,203	4,521	4,416
Total operating expenses	2,928	4,976	7,523	9,952
Operating loss	(1,538)	(3,697)	(5,074)	(6,996)
Other income (expense):
Interest income	27	67	28	139
Interest expense	—	(27)	(548)	(61)
Financing expenses	150	(3,545)	(3,061)	(3,545)
Warrant issuance costs	—	(432)	(964)	(432)
Change in fair value of derivative instruments	6,512	4,694	(2,631)	4,694
Total other income (expense)	6,689	757	(7,176)	795
Net income (loss)	$5,151	$(2,940)	$(12,250)	$(6,201)
Per share information
Net income (loss) per share of common stock – basic	$0.02	$(0.45)	$(0.50)	$(1.15)
Weighted average number of shares of common stock outstanding – basic	48,388,862	6,500,831	24,422,125	5,411,382
Net loss per share of common stock – diluted	$(0.01)	$(0.71)	$(0.50)	$(1.45)
Weighted average number of shares of common stock outstanding – diluted	209,154,994	10,742,924	24,422,125	7,532,428

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.